Aliment and Drug approves Zinebexos for multiple myeloma
The Saudi Food and Drug Authority has approved the registration of the product "Zinbexsus" (Epidromid) for the treatment of multiple myeloma in adults, making it the first regulatory authority in the world to approve this therapy. The medication is used as an adjunct treatment for patients experiencing relapse or resistant disease, working to break down proteins that contribute to the survival and growth of tumor cells, as well as enhancing the immune system's ability to attack cancer cells. Results from a third-phase clinical study demonstrated that combining "Epidromid" with "Daratumab" and "Dexamethasone" led to a significant improvement in patient condition. The product is associated with side effects, mainly a reduction in blood cells, which increases the risk of infection and anemia, and thus must be used under direct medical supervision. This approval underscores the Authority's commitment to supporting innovation and providing modern treatment options for patients in Saudi Arabia, in line with the goals of Vision 2030 and the Healthcare Transformation Program, aiming to accelerate access to innovative medications and improve the quality of healthcare services.
Notice: This Is an AI-Generated Summary
Comments (0)